Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis

Company Overview

Sonoma Pharmaceuticals, Inc. is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases. This approach is designed to enhance efficacy while minimizing skin irritation. The company’s lead product, Azclear® Foaming Gel, leverages azelaic acid to address papulopustular rosacea, and is complemented by additional prescription formulations and a suite of over-the-counter cleansers and medicated washes targeting acne-prone skin.

Headquartered in Santa Rosa, California, Sonoma Pharmaceuticals distributes its dermatology portfolio through physician offices, retail pharmacies and online channels across the United States. Under the leadership of President and Chief Executive Officer Mark D. Sirgo, the company is advancing its clinical pipeline and exploring strategic collaborations to expand its product offerings and reach new patient populations.

Key Stats

• Today's Range: $1.10 to $1.14
• 50-Day Range: $1.01 to $2.65
• 52-Week Range: $0.85 to $6.92
• Volume: 22,658 shs
• Average Volume: 123,696 shs
• Market Capitalization: $5.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Sonoma Pharmaceuticals Stock Analysis - MarketRank™

Sonoma Pharmaceuticals scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Sonoma Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Sonoma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sonoma Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sonoma Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sonoma Pharmaceuticals has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Sonoma Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Sonoma Pharmaceuticals has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sonoma Pharmaceuticals has recently decreased by 89.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sonoma Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Sonoma Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.44

News Sentiment

Sonoma Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Sonoma Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

Only 2 people have added Sonoma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.29% of the stock of Sonoma Pharmaceuticals is held by insiders.

Percentage Held by Institutions

1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 6/16/2026
• Today: 6/26/2026
• Next Earnings (Estimated): 7/15/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNOA
• CIK: 1367083
• Web: www.sonomapharma.com
• Phone: (800) 759-9305
• Fax: 707-283-0551
• Employees: 180
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): ($1.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.17 million
• Net Margins: -16.26%
• Pretax Margin: -17.51%
• Return on Equity: -43.95%
• Return on Assets: -11.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.50
• Quick Ratio: 1.75

Sales & Book Value

• Annual Sales: $19.53 million
• Price / Sales: 0.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.65 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 4,790,000
• Free Float: 4,676,000
• Market Cap: $5.34 million
• Optionable: Not Optionable
• Beta: 1.29